Skip to main content

Table 1 Breast cancer patients’ clinicopathological data of the testing and validation cohort #1

From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer

Clinicopathological featuresTesting cohortValidation cohort #1
Patients (n)1682
Age median (range)58 (35–78)49 (28–76)
Molecular subtypea (%)
 Luminal A-Like4 (25.0)19 (23.2)
 Luminal B-Like12 (75.0)58 (70.7)
 HER2-enriched1 (1.2)
 Basal-like/TNBC4 (4.9)
Histological type (%)
 Invasive carcinoma of NST13 (81.2)73 (89.0)
 Invasive lobular carcinoma3 (18.8)
 Other special subtype carcinoma
 Mixed type carcinoma9 (11.0)
Grade (%)
 G12 (12.5)4 (4.9)
 G24 (25.0)43 (52.4)
 G38 (50.0)35 (42.7)
 Gx2 (12.5)
ER receptor status (%)
 Positive16 (100.0)77 (93.9)
 Negative5 (6.1)
PR receptor status (%)
 Positive10 (62.5)65 (79.3)
 Negative6 (37.5)17 (20.7)
HER2 receptor status (%)
 Positive3 (18.8)15 (18.3)
 Negative13 (81.2)67 (81.7)
T Stage (%)
 T14 (25.0)20 (24.4)
 T29 (56.2)52 (63.4)
 T31 (6.3)5 (6.1)
 T42 (12.5)3 (3.7)
 Tx2 (2.4)
N Stage (%)
 N05 (31.2)18 (22.0)
 N17 (43.8)33 (40.2)
 N22 (12.5)16 (19.5)
 N32 (12.5)13 (15.9)
 Nx2 (2.4)
Stage (%)
 I3 (18.8)10 (12.2)
 II8 (50.0)34 (41.5)
 III5 (31.2)24 (29.3)
 IV12 (14.6)
 Not determined2 (2.4)
  1. ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor 2, NST no special type, PR progesterone receptor
  2. aAssessed by immunohistochemistry